Drug Database
Back to search

Poland· PL-100502055

Filspari

A other agents acting on the renin-angiotensin system product containing sparsentan, registered in Poland by Vifor France. The same ATC class is registered in 2 of our 19 countries.

ATC C09X

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFilspariATCC09XREGISTER NO.PL-100502055PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sparsentanAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sparsentan is registered in 2 of 19 countries.

Countries holding a registration under ATC C09X (other agents acting on the renin-angiotensin system), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose
Search sparsentan products by name

Sparsentan · ATC C09X

2 / 19 countries

  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Sparsentan
Manufacturer
Vifor France
Country
Poland (PL)
ATC code
C09X
ATC class
OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04150188292073

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Sparsentan in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sparsentan products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Filspari
  • Liechtenstein · Filspari
  • Norway · Filspari

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3c66168d-2573-4561-b974-886e4dbcb229
GET /v1/drugs/3c66168d-2573-4561-b974-886e4dbcb229?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "Rp ¦ EU/1/23/1788/002 ¦ 157347\n30 tabl.\n¦ UR/Z/4b/287/25 - 04150188292073\nRp ¦ EU/1/23/1788/003 ¦ 157348\n90 tabl. (op. zbiorcze)",
  "substance": "Sparsentanum 400 mg",
  "common_name": "Sparsentan",
  "pl_product_id": "100502055",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about sparsentan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console